A trial of switching then stopping treatment for chronic myeloid leukaemia (ENEST Path)

This trial is looking at switching treatment and then stopping treatment for chronic myeloid leukaemia (CML).

Doctors often treat CML with a biological therapy called imatinib (Glivec). Imatinib is a cancer growth blocker. It stops signals that cancer cells use to divide and grow. We know from research that CML responds to it so well in some people, that they can stop taking imatinib.

Nilotinib (Tasigna) is another biological therapy that is also a cancer growth blocker. We know from research that CML may respond better to nilotinib than imatinib.

The main aims of this trial are to find out

• If switching from imatinib to nilotinib can improve how well CML responds

• When people with CML can stop taking nilotinib after their leukaemia has responded to it